Libtayo® (cemiplimab) Approved in the European Union (EU) for Extended Dosing and Faster Infusion Times Across Skin, Lung and Cervical Cancer Indications
The European Commission approved a flexible dosing schedule for Regeneron's PD-1 inhibitor Libtayo across all six EU-approved indications in skin, lung and cervical cancers. The approval adds a 700 mg every-six-week maintenance option after 12 weeks of 350 mg every three weeks, and allows infusion times to be cut from 30 minutes to 15 minutes after a well-tolerated first infusion. A U.S.
Key figures
- Drug Name
- Libtayo (cemiplimab)
- Dosing regimen
- 700 mg every six weeks after initial 12 weeks of 350 mg every three weeks
- Us sbla decision
- March 2027
- Eu indications covered
- 6
- Infusion time reduction
- 30 minutes to 15-30 minutes after well-tolerated first infusion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.